Raymond James Financial Services Advisors’s ResMed RMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $6.36M | Buy |
26,057
+3,580
| +16% | +$800K | 0.01% | 1105 |
|
|
2024
Q2 | $4.3M | Sell |
22,477
-841
| -4% | -$171K | 0.01% | 1246 |
|
|
2024
Q1 | $4.62M | Buy |
23,318
+1,799
| +8% | +$330K | 0.01% | 1179 |
|
|
2023
Q4 | $3.7M | Buy |
21,519
+2,239
| +12% | +$344K | 0.01% | 1250 |
|
|
2023
Q3 | $2.85M | Sell |
19,280
-32,525
| -63% | -$5.88M | 0.01% | 1302 |
|
|
2023
Q2 | $11.3M | Buy |
51,805
+8,577
| +20% | +$1.91M | 0.02% | 665 |
|
|
2023
Q1 | $9.47M | Sell |
43,228
-443
| -1% | -$96.1K | 0.02% | 720 |
|
|
2022
Q4 | $9.09M | Buy |
43,671
+707
| +2% | +$155K | 0.02% | 692 |
|
|
2022
Q3 | $9.38M | Buy |
42,964
+724
| +2% | +$165K | 0.02% | 652 |
|
|
2022
Q2 | $8.86M | Sell |
42,240
-3,039
| -7% | -$647K | 0.02% | 677 |
|
|
2022
Q1 | $11M | Sell |
45,279
-2,513
| -5% | -$608K | 0.02% | 654 |
|
|
2021
Q4 | $12.4M | Sell |
47,792
-357
| -0.7% | -$92.6K | 0.02% | 600 |
|
|
2021
Q3 | $12.7M | Sell |
48,149
-1,383
| -3% | -$378K | 0.03% | 576 |
|
|
2021
Q2 | $12.2M | Sell |
49,532
-2,150
| -4% | -$452K | 0.02% | 593 |
|
|
2021
Q1 | $10M | Buy |
51,682
+1,138
| +2% | +$228K | 0.02% | 625 |
|
|
2020
Q4 | $10.7M | Sell |
50,544
-786
| -2% | -$157K | 0.03% | 529 |
|
|
2020
Q3 | $8.8M | Sell |
51,330
-11,501
| -18% | -$2.12M | 0.03% | 549 |
|
|
2020
Q2 | $12.1M | Buy |
+62,831
| New | +$10.3M | 0.04% | 415 |
|
|
2020
Q1 | – | Sell |
-56,868
| Closed | -$8.81M | – | 2782 |
|
|
2019
Q4 | $8.81M | Sell |
56,868
-1,571
| -3% | -$226K | 0.03% | 545 |
|
|
2019
Q3 | $7.9M | Buy |
58,439
+968
| +2% | +$127K | 0.03% | 537 |
|
|
2019
Q2 | $7.01M | Sell |
57,471
-180
| -0.3% | -$19.9K | 0.03% | 552 |
|
|
2019
Q1 | $5.99M | Buy |
57,651
+126
| +0.2% | +$13K | 0.02% | 584 |
|
|
2018
Q4 | $6.55M | Buy |
57,525
+831
| +1% | +$89K | 0.03% | 454 |
|
|
2018
Q3 | $6.54M | Buy |
56,694
+641
| +1% | +$70.2K | 0.03% | 546 |
|
|
2018
Q2 | $5.81M | Buy |
56,053
+2,573
| +5% | +$260K | 0.03% | 547 |
|
|
2018
Q1 | $5.27M | Buy |
53,480
+4,253
| +9% | +$402K | 0.03% | 529 |
|
|
2017
Q4 | $4.17M | Buy |
49,227
+241
| +0.5% | +$19.9K | 0.03% | 608 |
|
|
2017
Q3 | $3.77M | Buy |
48,986
+1,930
| +4% | +$148K | 0.02% | 638 |
|
|
2017
Q2 | $3.67M | Buy |
47,056
+1,306
| +3% | +$93.4K | 0.03% | 632 |
|
|
2017
Q1 | $3.29M | Buy |
45,750
+21,736
| +91% | +$1.5M | 0.03% | 620 |
|
|
2016
Q4 | $1.49M | Buy |
24,014
+556
| +2% | +$34.1K | 0.01% | 908 |
|
|
2016
Q3 | $1.52M | Sell |
23,458
-735
| -3% | -$48.9K | 0.01% | 879 |
|
|
2016
Q2 | $1.53M | Sell |
24,193
-3
| -0% | -$177 | 0.01% | 850 |
|
|
2016
Q1 | $1.4M | Sell |
24,196
-102
| -0.4% | -$5.77K | 0.02% | 769 |
|
|
2015
Q4 | $1.3M | Sell |
24,298
-1,402
| -5% | -$79K | 0.02% | 807 |
|
|
2015
Q3 | $1.31M | Buy |
+25,700
| New | +$1.38M | 0.02% | 670 |
|
Other funds holding RMD
Raymond James Financial Services Advisors's RMD Position: Q3 2024 in Review
Raymond James Financial Services Advisors increased its ResMed (RMD) stake by 16% in Q3 2024, buying an estimated $800K and bringing the position to 26,057 shares worth $6.36M. The position accounts for 0.01% of the portfolio, ranked #1105.
Raymond James Financial Services Advisors first reported a position in RMD in Q3 2015 and has held it in 36 quarters since. The position peaked at $12.7M in Q3 2021. 802 funds tracked by Wall St. Rank hold RMD as of Q3 2024.
- Raymond James Financial Services Advisors held 26,057 shares of ResMed worth $6.36M as of Q3 2024.
- Raymond James Financial Services Advisors bought 3,580 ResMed shares in Q3 2024, an estimated $800K.
- ResMed made up 0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #1105 holding.
- Raymond James Financial Services Advisors first reported a position in ResMed in Q3 2015 and has held it in 36 quarters since.
- Raymond James Financial Services Advisors's ResMed position peaked at $12.7M in Q3 2021.
- 802 funds tracked by Wall St. Rank held ResMed as of Q3 2024.
Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.